» Articles » PMID: 35895937

Cerebral Venous Sinus Thrombosis After COVID-19 Vaccination and Congenital Deficiency of Coagulation Factors: Is There a Correlation?

Abstract

In January 2020, SARS-COV-2 infection spread worldwide and was declared "pandemic" by WHO. Because of the high contagiousness of the virus and devastating effects of the epidemic on public health, numerous efforts have been made to develop suitable vaccines to prevent the infection. Among the side effects developed by patients who undergone vaccination, there are common symptoms but also more serious reactions such as the thrombosis syndromes. This paper presents two cases of thrombosis temporally associated with live-vectored Covid vaccination similar to vaccine-induced thrombocytopenia (VITT) in patients with inherited thrombophilia (respectively, the deficiency of protein S and a Factor II mutation). The clinical manifestation caused by VITT is characterized by widespread thrombosis especially affecting intracranial venous sinus, which may cause massive bleeding and intracranial hemorrhage. Although this condition is widely described in literature, there is no evident correlation between this side effect and inherited condition of thrombophilia. The authors suggest that the presence of inherited thrombophilia should be better investigated and, if necessary, screened during the anamnestic data collection before the vaccine administration, leading the healthcare professional to choose the appropriate vaccine to the patient.

Citing Articles

SARS-CoV-2 Vaccine Improved Hemostasis of a Patient with Protein S Deficiency: A Case Report.

Mohammad M, Malik A, Thangada L, Polania-Villanueva D, Zabaleta J, Majumder R Int J Mol Sci. 2024; 25(19).

PMID: 39409046 PMC: 11477061. DOI: 10.3390/ijms251910717.


Venous Thromboembolism Following COVID-19 Vaccination in Patients With Hereditary Protein S Deficiency.

Rayner M, Brose K J Hematol. 2024; 13(3):125-127.

PMID: 38993740 PMC: 11236358. DOI: 10.14740/jh1278.


Review of adverse events associated with COVID-19 vaccines, highlighting their frequencies and reported cases.

Yaamika H, Muralidas D, Elumalai K J Taibah Univ Med Sci. 2023; 18(6):1646-1661.

PMID: 37732332 PMC: 10507236. DOI: 10.1016/j.jtumed.2023.08.004.


People having hematological disorders and hypercoagulability state need extra precautions because of the increased risk of thrombosis after COVID-19 vaccination.

Aydemir D, Ulusu N Front Med (Lausanne). 2023; 9:1082611.

PMID: 36865660 PMC: 9971818. DOI: 10.3389/fmed.2022.1082611.


Histopathologically TMA-like distribution of multiple organ thromboses following the initial dose of the BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech): an autopsy case report.

Kaimori R, Nishida H, Uchida T, Tamura M, Kuroki K, Murata K Thromb J. 2022; 20(1):61.

PMID: 36203145 PMC: 9540301. DOI: 10.1186/s12959-022-00418-7.

References
1.
Ferrari E, Sartre B, Squara F, Contenti J, Occelli C, Lemoel F . High Prevalence of Acquired Thrombophilia Without Prognosis Value in Patients With Coronavirus Disease 2019. J Am Heart Assoc. 2020; 9(21):e017773. PMC: 7763401. DOI: 10.1161/JAHA.120.017773. View

2.
Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

3.
Borgel D, Gandrille S, Aiach M . Protein S deficiency. Thromb Haemost. 1997; 78(1):351-6. View

4.
Grifoni A, Weiskopf D, Ramirez S, Mateus J, Dan J, Rydyznski Moderbacher C . Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020; 181(7):1489-1501.e15. PMC: 7237901. DOI: 10.1016/j.cell.2020.05.015. View

5.
Ravichandran S, Coyle E, Klenow L, Tang J, Grubbs G, Liu S . Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. Sci Transl Med. 2020; 12(550). PMC: 7286538. DOI: 10.1126/scitranslmed.abc3539. View